Nevro Corp. (NVRO)
| Market Cap | 221.21M |
| Revenue (ttm) | 408.52M -3.9% |
| Net Income | -113.44M |
| EPS | -3.06 |
| Shares Out | 37.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 751,504 |
| Open | 5.84 |
| Previous Close | 5.84 |
| Day's Range | 5.84 - 5.86 |
| 52-Week Range | 3.17 - 13.84 |
| Beta | 0.82 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 6, 2025 |
About NVRO
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS systems. It also offers Senza HFX iQ platform that includes HFX iQ implantable pulse generator, HFX trial stimula... [Read more]
Financial Performance
In 2024, Nevro's revenue was $408.52 million, a decrease of -3.92% compared to the previous year's $425.17 million. Losses were -$113.44 million, 23.0% more than in 2023.
Financial StatementsNews
NVRO Metals Highlights Investment Potential of the NVRO Metals Hub Following Independent 77.6 Million-Tonne Mineral Resource Estimate
VANCOUVER, British Columbia, June 18, 2026 (GLOBE NEWSWIRE) -- NVRO Metals Limited (TSXV: NVRO) (“NVRO Metals” or the “Company”) is pleased to provide investors with additional context regarding the s...
NVRO Metals Announces Independent NI 43-101 Mineral Resource Estimate of 77.6 Million-Tonne Polymetallic Resource at the NVRO Metals Hub
VANCOUVER, British Columbia, June 18, 2026 (GLOBE NEWSWIRE) -- NVRO Metals Limited (TSXV: NVRO), (“NVRO Metals” or the “Company”), a clean technology company focused on the recovery of precious and cr...
Nevro Corp. Investigated by Federman & Sherwood for Data Breach
OKLAHOMA CITY, April 03, 2025 (GLOBE NEWSWIRE) -- Nevro Corp. investigated by Federman & Sherwood for data breach. On April 3, 2025, Nevro Corp. filed notice of a data breach with the Attorney General...
NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nevro...
Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results
REDWOOD CITY, Calif. , March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pa...
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
REDWOOD CITY, Calif. , Jan. 21, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pa...
Nevro Announces Preliminary Fourth-Quarter and Full-Year 2024 Revenue Results
Cash, Cash Equivalents and Short-Term Investments Increased Approximately $15.5 million in the Fourth Quarter of 2024 REDWOOD CITY, Calif. , Jan. 13, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a ...
New Study Demonstrates Multiple Advantages of Nevro1™, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral Approaches
Furthering Nevro's body of evidence as an innovation leader in pain management, da ta highlights the company's posterior integrated transfixation cage system REDWOOD CITY, Calif. , Nov. 18, 2024 /PRNe...
Nevro's HFX iQ™ Spinal Cord Stimulation with AI Technology Receives CE Mark Certification in Europe, Increasing Product Expansion Globally
HFX iQ is the first and only spinal cord stimulation (SCS) system integrating high-frequency SCS landmark evidence with cloud data insights, leading the way for personalized, data-driven patient care*...
Nevro Reports Third-Quarter 2024 Financial Results
Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA Guidance REDWOOD CITY, Calif. , Nov. 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device comp...
New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy
Analysis Marks the First Study of Spinal Cord Stimulation to Demonstrate Long-term, Significant, and Clinically Meaningful Reductions in HbA1c and Weight in Study Participants with Painful Diabetic Ne...
Nevro to Report Third-Quarter 2024 Financial Results and Host Earnings Conference Call on November 11, 2024
REDWOOD CITY, Calif. , Oct. 10, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, toda...
Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord Stimulation
HFX AdaptivAI combines insights from over 100,000 patients and more than 100 million data points¹ and leverages artificial intelligence (AI) to deliver responsive and personalized pain relief in real ...
Nevro to Present at Wells Fargo 2024 Healthcare Conference
REDWOOD CITY, Calif. , Aug. 28, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pa...
Nevro Reports Second-Quarter 2024 Financial Results
Initiates Process Aimed at Accelerating Growth, Diversifying Product Portfolio and Maximizing Stockholder Value Revises Full-Year 2024 Revenue Guidance to a Range of $400 million to $405 million and A...
Nevro to Report Second-Quarter 2024 Financial Results and Host Earnings Conference Call on August 6, 2024
REDWOOD CITY, Calif. , July 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today...
Nevro to Present at Truist Securities MedTech Conference
REDWOOD CITY, Calif. , June 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic p...
Nevro to Present at BofA Securities 2024 Healthcare Conference
REDWOOD CITY, Calif. , May 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain...
Nevro Reports First-Quarter 2024 Financial Results
Announces Additional Restructuring Steps to Advance Strategy and Accelerate Profitability Raises Adjusted EBITDA Guidance and Reaffirms Revenue Guidance for Full-Year 2024 Promotes Christofer Christof...
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
REDWOOD CITY, Calif. , April 17, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, tod...
Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw
Nevro1™ Proven to Immediately Transfix Sacroiliac (SI) Joint to Allow for Long-term SI Joint Fusion REDWOOD CITY, Calif. , Feb. 28, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical devi...
Nevro Enters Into Cooperation Agreement With Engaged Capital
Appoints Kirt P. Karros to Board of Directors REDWOOD CITY, Calif.
Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
Provides Full-Year and First-Quarter 2024 Guidance REDWOOD CITY, Calif. , Feb. 21, 2024 /PRNewswire/ --Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-...
Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy
Experts in diabetes, pain and health services from the Worldwide Initiative for Diabetes Education recommend spinal cord stimulation when symptoms aren't responsive to first- or second-line therapies ...
Nevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024
REDWOOD CITY, Calif. , Jan. 29, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pa...